术前分期PSMA显像中骨可疑病灶的意义:PSMA-RADS 1.0验证
该回顾性研究评估了406例根治性前列腺切除术前PSMA PET/CT分期患者中15例骨可疑病灶的临床意义。29个骨病灶中27个评分为3B,仅3个为真转移。结论认为大部分PSMA-RADS 3B骨病灶无临床意义,而PSMA-RADS 4/5骨病灶均为真阳性。
要点
- 术前分期中PSMA-RADS 3B骨病灶仅11%为真转移。
- PSMA-RADS 4/5骨病灶全部验证为真阳性。
- 大部分骨可疑病灶无临床意义,需结合随访判断。
核心结论
- 在中高危前列腺癌根治术前分期患者中,多数PSMA-RADS 3B骨病灶无临床意义。
- 评分为PSMA-RADS 4/5的骨病灶均验证为真阳性转移。
研究设计与样本
- 回顾性研究纳入406例连续根治性前列腺切除术前接受PSMA靶向PET/CT分期的患者。
- 其中15例存在骨可疑病灶,以术后PSA持续结合影像和组织学为参考标准。
- 扫描按PSMA-RADS 1.0回顾性评分,评分时对病程和随访数据设盲。
主要发现
- 其余患者评分为4(n=1)或5(n=1),均确认为真阳性前列腺相关恶性病灶。
- 病灶分析识别29个骨病灶,27个评分为PSMA-RADS 3B,仅3个为真转移。
- 争议病灶在84.6%的病例中无临床意义,PSMA-RADS 3B骨病灶仅11%为真阳性。
关键数值与推荐
- PSMA-RADS 3B骨病灶真阳性率为11%。
- 争议病灶无临床意义比例为84.6%。
- PSMA-RADS 4/5骨病灶均验证为真阳性。
临床怎么用
- 术前分期遇PSMA-RADS 3B骨病灶时,不应直接视为转移,需结合术后PSA和影像随访综合判断。
- PSMA-RADS 4/5骨病灶可信度较高,可按真阳性转移处理。
局限性
- 回顾性设计,仅15例骨可疑病灶患者,样本量小。
- 单中心研究,结论需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Assessing the extent of disease in newly diagnosed prostate cancer (PC) patients is crucial for tailoring an appropriate treatment approach. Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) reportedly has greater accuracy than conventional imaging for staging PC. As with any imaging modality, pitfalls and nonspecific findings do occur. The PSMA reporting and data system (PSMA-RADS) version 1.0 offers structured interpretation of PSMA-targeted studies and classifies lesions by likelihood of clinical significance. The aim of this retrospective study was to evaluate the clinical significance of equivocal bone findings on staging PSMA-targeted imaging, as defined by PSMA-RADS version 1.0, in the preoperative setting. Fifteen of 406 consecutive patients staged by PET/CT prior to radical prostatectomy had equivocal bone lesions. The scans were retrospectively scored with the PSMA-RADS version 1.0 system, blinded to disease course and follow-up data. Postoperative persistence of prostate-specific antigen levels supported by imaging and histological findings was used as the reference standard for the true significance of equivocal imaging findings. RESULTS: Thirteen of the 15 patients had an overall PSMA-RADS score of 3B, of whom only two had true metastatic disease. The remaining patients had scores of 4 (n = 1) or 5 (n = 1), all confirmed as true positive prostate-related malignant lesions. A per-lesion analysis identified 29 bone lesions, of which 27 were scored PSMA-RADS 3B, and only three of them were true metastases. Thus, debatable lesions proved to have no clinical significance in 84.6% of cases, and only 11% of equivocal PSMA-RADS 3B bone lesions were true positive. CONCLUSIONS: In intermediate and high-risk patients staged prior to radical prostatectomy, the majority of PSMA-RADS 3B lesions are of no clinical relevance. Bone lesions judged as being highly suspicious for metastases (PSMA-RADS 4/5) were all validated as true positives.
引用
- Kuten J, Dekalo S, Mintz I, et al. The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0. EJNMMI Res. 2021. PMID: 33409930. doi:10.1186/s13550-020-00745-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。